Pubblicazioni

The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements

2021 - ESMO OPEN

Delgado, J.; Pean, E.; Melchiorri, D.; Migali, C.; Josephson, F.; Enzmann, H.; Pignatti, F.

Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: Regulatory aspects

2020 - ESMO OPEN

Moscetti, L.; Hennik, P.; Bolstad, B.; Camarero, J.; Josephson, F.; Melchiorri, D.; Sommerfelt Gronvold, M.; Sjoberg, J.; Botezatu, M.; Mulder, J.; Meulendijks, D.; Trullas Jimeno, A.; Zafiropoulos, N.; Bergh, J.; Enzmann, H.; Pignatti, F.

European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

2019 - ESMO OPEN

Tzogani, K.; Florez, B.; Markey, G.; Caleno, M.; Olimpieri, O. M.; Melchiorri, D.; Hovgaard, D. J.; Sarac, S. B.; Penttila, K.; Lapvetelainen, T.; Salmonson, T.; Bergh, J.; Gisselbrecht, C.; Pignatti, F.